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Soy contains many bioactive molecules known to elicit anti-cancer effects. One
such peptide, Lunasin, has been shown to selectively act on newly transformed cells
while having no cytotoxic effect on non-tumorigenic or established cancer cell lines. In
this study we attempt to understand the developmental effects of Lunasin
overexpression in vivo and create reagents that will help us understand Lunasin’s anti
tumorigenic effects in an intact organism.
cDNA encoding lunasin and EGFP-lunasin were cloned into pUAST and
microinjected into Drosophila embryos. Tissue-specific overexpression of EGFP-Lun in
the resulting transgenic lines was accomplished by crossing transgenics to various GAL4
driver lines. Progeny were assessed for phenotypic alterations and no phenotypic
abnormalities were observed in tissues expressing EGFP-Lunasin, supporting current
studies that show Lunasin does not affect normal cells. Previous studies have localized
Lunasin to the nuclear compartment. To test if this was the case for EGFP-Lun,
subcellular localization of EGFP-Lun was determined via fluorescence microscopy.
Salivary glands from EGFP-Lun expressing individuals were dissected, fixed, and
mounted in Vectashield® with the nuclear stain, DAPI. Our results demonstrate that
EGFP-Lun, like native Lunasin, is localized to the nucleus. Eight transgenic lines were
viii

mapped to specific chromosomes and EGFP-Lun transgenic line GEJ1-L2 was balanced
in preparation for use in tumor suppression studies.
In summary, we have created and characterized transgenic flies capable of
overexpressing Lunasin under the control of the GAL4/UAS system. Localization of
EGFP-Lunasin to the nucleus and data on the phenotypic consequence of its
overexpression in flies is presented. Finally, reagents created as part of this thesis will
aid experiments aimed at understanding the effects of Lunasin on benign and invasive
tumors.

ix

1. INTRODUCTION
1.1 History of soy
Soy (Glycine max) has been a staple in the diets of many cultures for millennia.
Originally cultivated in Asia, soy arrived in Europe in the 1700s CE and by the 1800s
was being grown in the United States. There are many health benefits associated with
soy rich diets. Soy consumption lowers the so-called bad cholesterol (LDL) (CARROLL
and KUROWSKA 1995; SIRTORI et al. 1995) and reduces risk of coronary disease and
cancers, particularly breast, colon, and prostate (LIU and PAN 2010). Soybeans contain
many bioactive compounds with demonstrated anticancer activity including isoflavones,
protease inhibitors (most noted is the Bowman-Birk protease inhibitor, BBI), saponins,
and more recently the peptide Lunasin (MESSINA and BARNES 1991).
Lunasin was discovered while isolating the 2S cDNA which codes for a nutrient
enhancing, methionine-rich albumin protein in soy (ODANI et al. 1987). The isolated
gene, Gm2S-1, codes for the methionine-rich protein, and three additional peptides: a
signal peptide, a linker peptide, and Lunasin (Figure 1)(GALVEZ et al. 1997). Lunasin
has also been found in wheat (JEONG et al. 2007a), barley (JEONG et al. 2010), amaranth
(SILVA-SÁNCHEZ et al. 2008), pepper(HERNÁNDEZ-LEDESMA and DE LUMEN 2008), rye
(JEONG et al. 2009), oats (NAKURTE et al. 2013), and the herb Solanum nigrum (JEONG et
al. 2007b). As Lunasin has been isolated from a variety of angiosperm seeds, a more
thorough screening will likely reveal Lunasin in many additional sources. However, to
date, soy remains the richest source of Lunasin.
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Figure 1. Primary structure of Gm2S-1 albumin
Gm2S-1 is comprised of four peptides: a signal peptide (residues 1-21), Lunasin (residues
22-64), a Gm2S-1 linker peptide (residues 65-81), and alisin (residues 82-158). (Adapted
from (DE LUMEN and GALVEZ 2003).
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1.2 Structure of Lunasin
Lunasin is a 43 amino acid peptide with a predicted helical region with homology
to chromatin binding protein, and a carboxyl terminal cell adhesion motif (ArginineGlycine-Aspartic acid, RGD) followed by a run of eight aspartic acid residues (Poly-D
tail) (Figure 2; (GALVEZ and DE LUMEN 1999). The poly-D tail, N-terminus, and
predicted helix are shown to be essential for the bioactivity of Lunasin; however, there is
conflicting evidence as to whether the RGD motif is essential for the anti-cancer effects
(Table 1) (GALVEZ and DE LUMEN 1999; LAM et al. 2003). The Poly-D tail binds to
deacetylated histones and is necessary for the antimitotic effect of Lunasin as
demonstrated by Galvez and de Lumen (1999) in both murine hepatoma cells and
Escherichia coli (E. coli) cells. Transfection of murine hepatoma cells with full-length
lunasin resulted in a diffused chromosomal mass, indicative of mitotic disruption,
whereas transfection with a Poly-D deletion mutant resulted in a loss of antimitotic
activity (i.e. chromosomal DNA appeared normal and there were no morphological
changes). Moreover, E. coli expressing full-length Lunasin exhibited reduced bacterial
growth and abnormal filament formation, whereas E. coli expressing a Lunasin-Poly-D
deletion mutant exhibited normal septa formation and normal division (GALVEZ and DE
LUMEN 1999), supporting the claim that the Poly-D tail is essential for the bioactivity of
Lunasin.

3
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(Adapted from (KYLE et al. 2012)

RGD cell adhesion motif (residues 33-35), and a poly-D tail (residues 35-43).

Lunasin is a 43 amino acid peptide with a predicted chromatin binding helical domain (residues 23-32), an

Figure 2. Primary structure and motifs of Lunasin
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mutants lose bioactivity.

that lunasin lacking the RGD motif retains bioactivity, whereas Galvez and De Lumen (1999) argue that RGD-deletion

However, there are conflicting reports on the necessity of RGD motif the retain bioactivity as Lam et al. (2003) claim

mitotic molecule. The N-terminus and poly-D tail are both essential for the anti-mitotic bioactivity of lunasin.

Two studies have explored the motifs of lunasin and have agreed that full length lunasin is bioactive and acts as an anti-

Table 1. Motifs of Lunasin

The sequence from the N-terminus to the predicted helix is also necessary for the
full bioactivity of Lunasin. Lam et al. demonstrated that an N-terminus deletion mutant
was only about one third as effective as full-length Lunasin at preventing foci formation
in NIH 3T3 cells (LAM et al. 2003).
The RGD cell adhesion motif is thought to be responsible for the internalization
of Lunasin. Galvez et al. (2001) reported that an RGD-deletion mutant failed to prevent
chemically induced transformation of mouse embryonic fibroblasts (C3H 10T1/2). The
lack of bioactivity was due to an inability of Lunasin to be internalized by cells and thus
it was concluded that the RGD motif is necessary for internalization of Lunasin (GALVEZ
et al. 2001). In a later study by Lam et al., Lunasin lacking the RGD motif was only
slightly less effective at preventing transformation of mouse embryo fibroblasts
(NIH3T3) compared with non-mutated Lunasin. Additionally, they reported that RGDdeletion mutants are internalized into the nucleus as effectively as full-length Lunasin,
demonstrating that the RGD motif is not required for internalization (LAM et al. 2003).
Lam et al. propose that this discrepancy in the data is due to differences in internalization
mechanisms between cell lines (NIH3T3 and C3H 10T1/2).

1.3 Proposed mechanisms of action
Natural role in soy
Lunasin is found in abundance in developing soy cotyledons. There are three
stages in the development of the cotyledon: (1) a phase of rapid cell division followed by
(2) a cessation of mitosis, during which time cells grow larger and acquire and store
nutrients, and (3) the dehydration of the seed. The expression of Lunasin coincides with
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mitotic arrest. It is thought that Lunasin may play a role in triggering the arrest of cell
division because of its demonstrated anti-mitotic activity in vitro (JEONG et al. 2003).

Effects on tumorigenic and non-tumorigenic lines
Lunasin exhibits no cytotoxic or anti-mitotic effects on non-tumorigenic or
established cancer cell lines (DIA and GONZALEZ DE MEJIA 2011; GALVEZ et al. 2001;
LAM et al. 2003; PABONA et al. 2012). When treated or transfected with Lunasin, these
cells show normal growth and cell division. In contrast, in cells newly transformed by
chemical carcinogens or viral oncogenes, Lunasin has been shown to suppress
transformation, arrest cell division, and induce chromosomal fragmentation and apoptosis
(DIA and GONZALEZ DE MEJIA 2011; GALVEZ et al. 2001; LAM et al. 2003; PABONA et al.
2012).

Inhibition of Core Histone Acetylation
Under steady-state conditions, core histones are typically in a repressed,
deacetylated state. During a transformation event the histones are acetylated, which
relaxes the chromatin, and results in the initiation of transcription (GALVEZ et al. 2001).
Interruption of acetylation is perceived by the cell as abnormal, and in response the cell
commits itself to apoptosis. Lunasin competes with histone acetyl-transferases (HATs) to
bind the histones that are exposed during transformation events (GALVEZ et al. 2001). If
HAT binds, transcription is initiated, S phase proteins are produced, and mitosis
progresses. However, binding of Lunasin to exposed, deacetylated histones disrupts the
acetylation process. This results in commitment of the newly transformed cells to
apoptosis, thereby preventing the replication of neoplastic cells (DE LUMEN 2005). In this
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way, de Lumen et al. liken Lunasin to a “watchdog”, whereby Lunasin sits idly in the
nucleus waiting for a transformation event to occur before jumping to action, inhibiting
the replication of newly transformed cells (DE LUMEN 2005).

Inhibit mitosis by increasing expression of CDK-inhibitors, p21 and p27
Cyclin-dependent kinases (CDKs) are important in controlling cell cycle
progression (MALUMBRES and BARBACID 2009). Deregulation of the cell cycle is
attributed to low levels of CDK inhibitors, such as p21 and p27, and is a hallmark of
transformed cells (XIONG et al. 1993). Additionally, low levels of p27 are correlated with
a poor prognosis in breast cancer patients (STEEG and ABRAMS 1997). Lunasin has been
shown to increase the expression of p21 and p27, resulting in an arrest at the G2/M stage
in transformed colon cancer cells (KM12L4) and mouse embryonic fibroblasts (NIH3T3)
(DIA and GONZALEZ DE MEJIA 2011; LAM et al. 2003).
Additionally, earlier work has shown that a reduction in p21 and p27 gene
expression correlated with an increase in drug resistance (ABUKHDEIR et al. 2008; CHU et
al. 2007). It is possible that the increased levels of these CDK-inhibitors, as induced by
Lunasin, will reduce the prevalence and slow the rise of drug resistance in patients.

Decrease metastasis via modification of expression of ECM genes
Angiogenesis and metastasis are often preceded by deregulation and degradation
of the extracellular matrix (ECM). Lunasin has been found to modify the expression of
numerous genes involved in cell-adhesion and ECM regulation (Table 2;(DIA and
GONZALEZ DE MEJIA 2011). Although several matrix metalloproteases (MMPs), which
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Table 2. Effect of Lunasin on gene expression of extracellular matrix and cell
adhesion in human KM12L4 colon cancer
(+) Values represent upregulated genes and (-) values represent those
downregulated by lunasin. (Table from(DIA and GONZALEZ DE MEJIA 2011).
9

contribute to the breakdown of the ECM, are upregulated (average of 2.05 fold; n=7) in
the presence of Lunasin, MMP10 is considerably downregulated (7.71 fold).
Additionally, Lunasin upregulated the expression of COL14A1 (collagen, type XIV, α1),
a protein that, when knocked down, results in increased cell proliferation in renal cell
carcinoma cell lines (DIA and GONZALEZ DE MEJIA 2011).
α5β1 integrin plays a key role in cell adhesion, growth, and proliferation (LU et
al. 2006). Elevated levels of α5β1 are associated with increased invasiveness of colorectal cancer (CRC) cell lines (GONG et al. 1997) and loss of α5β1 function results in
decreased metastasis in CRC cells (STOELTZING et al. 2003). Lunasin is able to
downregulate the expression of α5 integrin and has the most potent anti-mitotic effect on
cell lines which highly express the α5β1 integrin (DIA and GONZALEZ DE MEJIA 2011),
suggesting a role as an anti-metastatic molecule.

Induce apoptosis by activating the mitochondrial apoptosis pathway
Mitochondrial-mediated apoptosis can be triggered by a change in membrane
permeability, which is regulated by proteins in the Bcl-2 super family and cytochrome c
(TSUJIMOTO et al. 2006). Lunasin has been found to activate the mitochondrial apoptosis
pathway in colon cancer cells (KM12L4) by increasing levels of pro-apoptotic molecules
such as Bax, nuclear clusterin, and caspases 2, 3, and 9, while reducing the expression of
Bcl-2, a pro-survival molecule (DIA and GONZALEZ DE MEJIA 2011).

Reduce inflammation by inhibiting proinflammatory cytokines
Chronic inflammation has long been implicated as an initiating factor in many
cancers (colon, liver, bladder, and stomach) (COUSSENS and WERB 2002). During times
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of inflammation, leukocytes induce DNA damage through the production of genotoxins
including reactive oxygen species (ROS) and nitric oxide (NO). Recently, it has been
suggested that Lunasin may help reduce inflammation by inhibiting the release of NO
and the pro-inflammatory cytokines, TNF-α and IL-1β (LIU and PAN 2010). The
discovery of the anti-inflammatory effects attributed to Lunasin may be significant in the
search for therapeutics for other ailments directly caused or amplified by inflammation
including arthritis, heart disease, diabetes, and Alzheimer’s disease.

Upregulate the tumor suppressor, PTEN
PTEN, a phosphatase and tensin homolog, is a tumor suppressor that plays a
regulatory role in cell cycle progression and apoptosis, and is often found mutated or
downregulated in cancers (SIMPSON and PARSONS 2001; TAMURA et al. 1998). Genistein,
a soy isoflavone, has been found to impart antitumor effects via activation of PTEN
pathways (DAVE et al. 2005; RAHAL and SIMMEN 2009), leading researchers to question
if Lunasin shares this anti-tumor mechanism. Pabona et al. found that human breast
cancer cells (MCF-7) treated with Lunasin exhibited elevated levels of PTEN expression
and nuclear localization, and induced apoptosis via the PTEN pathway (PABONA et al.
2012).

1.4 Lunasin as a Natural Chemotherapeutic
Aside from the demonstrated benefits of Lunasin, public opinion may very well
play a role in the development of Lunasin as a therapeutic. Society is beginning to place
a high value on products derived from natural sources in order to reduce our dependence
on manmade chemicals which often have unforeseen side-effects. Because of the
11

multitude of anti-cancer pathways influenced by Lunasin, this short peptide holds
promise in combating numerous cancers, including those which have developed drug
resistance. The next stage in Lunasin research is to test the efficacy of Lunasin in vivo. I
argue that Drosophila is the natural choice for a model organism.
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“The idea was to learn about the general by studying the particular; to use a specific
organism as a model for all others.” – Kellogg and Shaffer, 1993
(KELLOGG and SHAFFER 1993)

1.5 Drosophila as a model organism
Since the time of Thomas Hunt Morgan, Drosophila has been a powerful model
organism. Morgan originally chose the fruit fly because of the ease of collection, fast
generation time, and small size. Since his time, much information has been collected that
leads researchers to continue to choose Drosophila as a model organism.
The power of Drosophila as a model lies in the simplicity of conducting genetic
screens made possible by the ease and affordability of rearing multiple generations in a
short period of time. Drosophila has an eight to ten day life cycle (Figure 3) at 25 °C
with females laying between 500 and 1000 eggs per animal (HANSON and FERRIS 1929).
Vast quantities of eggs allow researchers to analyze hundreds or even thousands of
mutant lines over multiple generations, a feat matched only by bacteria and yeast
(BECKINGHAM et al. 2005).
Drosophila has a streamlined genome consisting of four chromosomes. Although
once thought to have only 5,000 genes (GARCIA-BELLIDO and RIPOLL 1978), due to the
complete sequencing of the Drosophila genome in 2000 (ADAMS et al. 2000), it is now
known that Drosophila has approximately 13,600 genes (ADAMS et al. 2000); a relatively
low number as compared to the estimated 20-30,000 genes in humans (VENTER et al.
2001). Due to the small amount of genetic material, Drosophila has relatively little
genetic redundancy as compared to vertebrate models (BECKINGHAM et al. 2005). This
allows for easier genetic mapping and balancing (discussed below).
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Figure 3. Life cycle of Drosophila at 25 °C
Mated females lay embryos and first instar larvae hatch approximately 24 hrs
later. First instar larvae consume as many nutrients as possible before molting
and becoming second instar larvae. One day later, the second instar larvae molt
and become third instar larvae. The third instar larvae continue to acquire as
many nutrients as possible before pupating. Three to five days after pupation,
adult flies eclose. Within six hours after eclosing, flies are sexually mature.
(Figure adapted from(WEIGMANN et al. 2003)
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Perhaps the most important aspect of a model organism is the ability to draw
comparisons to other organisms. As many processes and biochemical pathways are
conserved from flies to humans (BECKINGHAM et al. 2005), Drosophila provides an
informative model with which to study human disease states. About 80% of human
genes have homologues in Drosophila and about the same percentage of identified
human disease genes have Drosophila cognates (75%) (REITER et al. 2001; ST. JOHN and
XU 1997).

1.6 Availability of a sophisticated tool box in Drosophila
The expansive ‘tool box’ that exists for Drosophila research is rivaled only by
bacteria and yeast, making fruit flies a very attractive model. The iconic tool used by
Drosophila geneticists is non-lethal phenotypic mutations (e.g. red eye, w+). These
mutations allow researchers to follow specific genes as well as whole chromosomes
through multiple generations. The use of these mutations has led to the development of
another powerful tool, balancer chromosomes.
Balancer chromosomes are chromosomes that contain multiple inversions capable
of suppressing crossover events between homologous chromosomes during meiosis.
These chromosomes are marked by dominant, homozygous lethal mutations (e.g. CyO,
Tb, Sb, ScO, etc.) and allow investigators to (1) maintain recessive lethal mutations in a
population and (2) to know the genotype of individuals without having to genotype each
animal (BELLEN et al. 2010). Balancer chromosomes are available for the X
chromosome, as well as all three Drosophila autosomes.
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The GAL4/UAS system is a tool derived from yeast which allows for tissue
specific overexpression of a gene of interest (BRAND and PERRIMON 1993). GAL4 is a
transcription activator protein that binds to the UAS (Upstream Activation Sequence)
enhancer element and drives expression of downstream genes (Figure 4). GAL4
expression can be spatially restricted by placing GAL4 under the control of tissue
specific proteins (e.g. GMR-GAL4 expresses GAL4 in the eye). By forcing the ectopic
expression of a gene, it is possible to study the biology of an otherwise lethal gene in vivo
(POTTER et al. 2000).
There exist a number of GAL4 driver lines that allow for the expression of GAL4
in specific tissues (Table 3) and can be obtained from Bloomington Stock Center
(http://flystocks.bio.indiana.edu/). In practice, one need only create a transgenic line with
a UAS-cDNA construct for a gene of interest and cross that to a GAL4 driver line that
expresses GAL4 in the desired tissue. The resulting progeny will have both the activator
protein (GAL4) and the target gene and will therefore express the gene of interest only
where GAL4 is expressed (Figure 4).
Mosaic Analysis with a Repressible Marker (MARCM) is a technique that
combines GAL4/UAS and a recombination system (Flipase/Flipase Recombination
Target (FLP/FRT)). MARCM allows researchers to create fluorescently labeled (Green
Fluorescent Protein, GFP) clones that are homozygous for a target gene in an otherwise
heterozygous animal (LEE and LUO 1999). This can be used in the study of tumor microenvironments by creating clones which express an activated oncoprotein (e.g. RasV12),
effectively creating fluorescently labeled tumors (MILES et al. 2011; SRIVASTAVA 2013).
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Figure 4. Schematic of GAL4/UAS gene expression technique
Virgins from a GAL4 driver line are mated with transgenic males containing a UAS
construct (a GFP fusion is shown here). Progeny (F1) will contain both the GAL4 driver
and the UAS construct and are therefore capable of expressing genes directly
downstream of the UAS (BRAND and PERRIMON 1993).
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GAL4 Driver

Genotype

GAL-4 Expression Location

Collagen

Cg-GAL4, UAS-GFP/CyO

hemocytes

Eyeless

w; Ey-GAL4/CyO

eye disc, ventral nerve cord,
brain

GMR-GAL4

eye

w; LSP2-GAL4

third instar fat body

Pannier

Pnr-GAL4/TM6Tb

dorsal cells along the length of
fly

Patched

Ptc-GAL4, UAS-GFP

antero-posterior compartment
boundary

Sd-GAL4 (x)

wing

yw;; Tub-GAL4/TM3Sb

ubiquitous (tubulin)

Ultrabithorax

w;; Ubx-GAL4/Tb

abdomen, haltere, wing

Vestigial

Vg-GAL4 (M+Q)

wing imaginal disc

Glass Multiple
Reporter
Larval serum protein 2

Scalloped
Tubulin

Table 3. GAL4 driver lines chosen for this study.
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1.7 Biomedical advances attributed to fruit fly research
Fruit flies have been used to model a variety of diseases and genetic disorders.
From diseases associated with aging (MICHNO et al. 2005) to neurological diseases such
as Alzheimer’s and Parkinson’s diseases (BECKINGHAM et al. 2005; MUQIT and FEANY
2002), Drosophila provides a valuable model to understand disease states in humans and
has led to many advances in modern medicine.
One such advancement in medicine is the approval of a therapeutic for the
treatment of tuberous sclerosis (TS). In patients with TS, tumors develop in multiple
organs. Research on Drosophila elucidated the signaling pathway responsible for the
misregulation of tissue growth, and furthermore led to the discovery that reducing the
expression of a gene (S6 kinase) prevents this misregualtion (TANENBAUM 2003).
Rapamycin is a drug known to inhibit a portion of the S6 kinase pathway, and was
approved by the FDA for clinical trials in TS patients. In 2008, Bissler et al. published
findings that a 12 month regimen of Rapamycin resulted in a decrease in
angiomyolipomas in 50% of patients (BISSLER et al. 2008).

1.8 Modeling of tumors in Drosophila
Many Drosophila genes have homologs to human oncogenes and tumor
suppressors making Drosophila a powerful/useful model to study tumorigenesis and
metastasis. Potter et al (2000) identified more than fifty Drosophila genes with cognates
to mammalian tumor genes (Table 4). Research on Drosophila has led to the elucidation
of a number of pathways that directly regulate tumor development in humans including
the Notch, Hippo, JAK-STAT, LATS, and Hedgehog signaling pathways
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of Drosophila as a model for tumor studies. (From (POTTER et al. 2000)

Potter et al. amassed a list of over 50 tumor related fly genes that have homologues to human genes demonstrating the relevance

Table 4. Fly homologues to mammalian genes

(ALLENSPACH et al. 2002; MILES et al. 2011; POTTER et al. 2000; WATKINS et al. 2003).
The Notch signaling cascade, which has been implicated in several human cancers
including breast, ovarian, and skin cancers, was first identified in flies (ALLENSPACH et
al. 2002; MILES et al. 2011). Additionally, genetic screens in Drosophila led to the
identification and characterization of three key genes involved in the Hedgehog pathway
which is a major regulator of tissue growth and is linked to the transformation of healthy
tissue to tumors in several cancers (BECKINGHAM et al. 2005; WATKINS et al. 2003).
While studies of cell cultures provide invaluable information, Drosophila affords us the
opportunity to study the microenvironments of tumors in situ. Using our vast toolbox, we
can readily manipulate cancer related genes in vivo and visualize the effects on tumor
growth and metastasis.

1.9 Modeling of metastasis in Drosophila
The majority of cancer fatalities in humans are attributed to secondary metastatic
growth (CHAMBERS et al. 2002). Drosophila provides a useful model for studying
metastasis as many biochemical mechanisms and pathways associated with metastasis are
conserved between humans and flies (e.g. ECM turnover) (POTTER et al. 2000).
There are several established systems in Drosophila which allow us to study
metastasis. One such model is the RasV12/lgl model (PAGLIARINI and XU 2003;
SRIVASTAVA 2013). Ras is an oncogenic protein and RasV12 codes for an activated
isoform of the protein. Flies overexpressing RasV12 exhibit benign, non-metastatic
tumors. However, when combined with lethal giant larvae, a tumor suppressor encoded
by the gene lgl, aggressive metastatic tumors result (PAGLIARINI and XU 2003;
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SRIVASTAVA 2013). Thus we can induce a metastatic tumor by creating Drosophila with
a genetic background of RasV12/lgl.

1.10 Limitations of Drosophila as a tumor model
Although there are structures in flies that perform similar functions to mammalian
organs (e.g. Drosophila Malpighian tubules and mammalian kidneys;(SINGH and HOU
2008), several human organs have no direct homologous organ in flies. This can make
modeling of organ specific cancers difficult. Regardless, there is much to be learned
about the highly conserved biochemical characteristics of tumors that can be studied by
mimicking tumor environments in the fly.
Instead of blood vessels, Drosophila, like all members of the phylum Arthropoda,
utilize an open circulatory system. Hemolymph serves as their nutrient transport system
and the hemocoel, an open cavity, houses and transports hemolymph. Although true
angiogenesis does not occur in Drosophila, in tumors produced by mutations in the lats
gene, “lumen like” structures, resembling blood vessels, form and serve to distribute
nutrients (POTTER et al. 2000), mimicking angiogenesis. In this way, we are able to study
angiogenesis in flies as it relates to tumors; however, care must be taken to ensure
conclusions are not overstated.
Lunasin is currently a focus of investigation for its role as a potential anti-cancer
therapeutic. This study aimed to create tools that will help determine whether Lunasin,
when expressed in vivo, exerts any effect on normal development and tumor progression.
We attempted to (1) create transgenic Drosophila capable of overexpressing Lunasin, (2)
assess the effects of Lunasin on normal development, and (3) balance transgenic
Drosophila in preparation for tumor suppression studies.
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2. MATERIALS AND METHODS
2.1 Construction of transgenic flies capable of expressing Lun and EGFP-Lun
Design and synthesis of DNA encoding lunasin and EGFP-lunasin
The experimental design required two gene constructs: lunasin and a fluorescently
tagged lunasin. The Lunasin DNA sequence was obtained from published reports. To
untagged lunasin, a start and stop codon were added to the 5’ and 3’ ends, respectively.
For fluorescently tagged lunasin, the EGFP (Enhanced Green Fluorescent Protein)
sequence was fused in silico to the lunasin DNA sequence on the 5’ end according to
published reports. In both constructs, restriction sites for EcoRI and XhoI were added to
the 5’ and 3’ end, respectively. Once designed, these sequences were synthesized in vitro
and the sequence verified by Integrated DNA Technologies (IDT;
http://www.idtdna.com/site). The synthesized DNA was received from IDT in the
proprietary vector, pIDTSMART.

Cloning of lunasin and EGFP-lunasin into pUAST
Plasmids were digested with EcoRI and XhoI. Restriction digests of pUAST and
the pIDTSMART plasmids containing the synthesized genes were set up in 20 μL
aliquots as follows: 1 µL EcoRI, 1 µL XhoI, 2 µL 10X buffer H, <1 µg plasmid, and
sterile water to bring the volume up to 20 µL (Invitrogen; cat. nos. 10502 and 15231).
The reaction mixture was incubated at 37 °C for 1 hr in a thermal cycler (Protocol 1) and
subsequently electrophoresed on a 1% agarose gel. The agarose gels were stained with
either 0.02 mg ethidium bromide (10 mg/mL) or 3 µL, 10,000 X GelRed® (Biotium; cat.
no. 41003) added to molten agarose. Loading dye, 10 X, was mixed with DNA was
mixed to a final concentration of 1X (Invitrogen; cat. no. 10816) and loaded alongside a
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1Kb Plus DNA ladder (Invitrogen; cat. no. 10787;Supplementary figure 3) and was
electrophoresed for 60 minutes at 100 V.
Electrophoresed DNA was gel extracted utilizing the QIAEX II gel extraction kit
according to manufacturer’s instructions (QIAGEN; cat. no. 20021;Protocol 2).
Ligations of pUAST and EGFP-lunasin were set up in 10 µL reactions with a
vector: insert ratio of 1:22. Reactions were set up as follows: 50 ng pUAST digested
with EcoRI and XhoI, 105 ng EGFP-lun digested with EcoRI and XhoI, 0.5 µL ligase,
and 1 µL ligase buffer (New England BioLabs; cat. no. M0202S.) Ligations of pUAST
and lunasin were set up in 20 µL reactions with a vector: insert ratio of 1:9 as follows:
175 ng pUAST, 25 ng lunasin, 1 µL ligase, and 2 µL ligase buffer. All ligation reactions
were incubated at 10 °C for 16 hr in a thermal cycler (Protocol 3).
Ligated plasmids (pUAST::EGFP-lun and pUAST::lun) were transformed into
DH5α Escherichia coli (E. coli) cells as follows: cells were thawed and kept on ice.
Between 50 and 150 µL cells were combined with 10 µLs of ligation reaction, and
incubated on ice for 20 min. The mixture was then heat shocked at 42 °C for 90 s, and
immediately placed on wet ice for 2 min. 300 µL of Luria broth (LB) (SIGMA; cat. no.
L7275) was added to the transformation mixture and the transformation mixture was
incubated at 37 °C for 45 min in a shaking incubator. A portion of the transformation
mixture (between 100 and 200 µL) was plated on LB-agar plates containing Ampicillin
(SIGMA; cat. no. A0166-5G) at a final concentration of 50 µg/mL. Plates were inverted
and incubated at 37 °C for 16-20 hr (Protocol 4).

Confirmation of successful cloning
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Transformants carrying the putative pUAST recombinant constructs were
inoculated in 5 mL LB broth with Ampicillin (50 μg/mL) and incubated for 12-16 hrs at
37 °C. Plasmids were subsequently isolated utilizing a QIAGEN Plasmid Plus Mini kit
(QIAGEN; cat. no. 27104;Protocol 5).
To confirm successful cloning of pUAST::EGFP-lun, plasmids were digested
with EcoRI and XhoI (Protocol 1) and the sample electrophoresed in a 1% gel stained
with 0.02 mg Ethidium Bromide (10 mg/mL) added to molten agarose.
To confirm successful cloning of pUAST::lun, we first performed whole colony
PCR of putative pUAST::lun transformants utilizing two oligonucleotide primers that
flank Lunasin: pUAST.FOR and GEJ.pUAST.REV (Table 5). Reactions were set up as
follows: 22.5 µL SuperMix (Invitrogen; cat. no.10572-014), 200 nM pUAST.FOR, 200
nM GEJ.pUAST.Rev, and water added to 25 µL. PCR amplification parameters were as
follows: initial denaturation at 95 °C for 3 min; 30 cycles of denaturation at 95 °C for 40
s, primer annealing at 57 °C for 30 s, and extension at 72 °C for 30 s; final extension at
72 °C for 4 min (Protocol 6).
Bacterial stocks confirmed to contain the pUAST recombinant plasmids were
inoculated in 400 mL LB broth with Ampicillin (50 μg/mL) and plasmids subsequently
isolated utilizing QIAGEN Plasmid Plus Maxi kit (QIAGEN; cat. no. 12963; Protocol 7).
The pUAST::lun and pUAST::EGFP-lun constructs were sequenced as follows: 2
μL 5X BigDye® Terminator v1.1/3.1sequencing buffer, 2 μL Ready Reaction premix
(ABI; cat. no. 4336917), 0.5 μL UAAS-2 primer (Table 5), 20 ng template DNA, and
water to 10 μL. Reactions were run for 25 cycles as follows: 30 sec denaturation at 95
°C, 15 sec annealing at 50 °C, and 4 min extension at 60 °C. PCR products were cleaned
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using a QIAGEN DyeEx® Spin kit (QIAGEN; cat. no. 63206) according to
manufacturer’s directions. Reactions were dried in a speedvac for 15 min with no heat,
and re-suspended in 20 μL Hi-Di Formamide (Applied Biosystems; cat. no. 4311320).
Samples were then loaded into ABI Prism sequencer and analyzed via ABI Prism
software.

Microinjection of recombinant constructs (*performed by GSI)
Microinjection of the plasmid constructs was performed by Genetic Services
Incorporated. Briefly, plasmid constructs and helper plasmids coding for transposases
were injected into the posterior end of Drosophila embryos where germ cells are located.
Successfully transformed individuals were screened for w+, red eyes.

2.2 Assessing the effects of EGFP-Lunasin on normal development
Confirmation of EGFP-Lun expression
To confirm EGFP-Lun expression, UAS-EGFP-lun transgenics were crossed to a
Tubulin-GAL4 line which drives ubiquitous transgene expression. Progeny were
screened for fluorescence as an expression indicator.
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Table 5. Primers used in this study

Evaluation of EGFP-Lun effects on normal development
EGFP-Lun transgenics were crossed to several GAL4 driver lines (Table 3).
Crosses were set up in vials with nutrient agar (LabExpress; cat. no. 7002) using five
virgins (☿) from GAL4 driver lines and five male (♂) transgenic flies. Individuals
determined to express EGFP-Lun were carefully assessed to evaluate developmental
effects. Legs, thorax, abdomen, and head were visually examined to identify any
phenotypic abnormalities.

Confirmation of nuclear localization of EGFP-Lun
Nuclear localization of EGFP-Lun was determined by imaging salivary glands
stained with Vectashield® mounting medium containing DAPI (Vector Labs; cat. no. H1200). Salivary glands were first dissected in chilled 1X PBS (137 mM NaCl + 2.68 mM
KCl + 10.14mM Na2HPO4 + 1.76 mM KH2PO4) and the glands fixed for 10-20 minutes
in a fixative (0.1 M PIPES pH 7.2 + 4% paraformaldahyde), followed by two washes
with a wash buffer (1XPBS + 0.1 % TritonX-100 + 0.01% sodium azide). The discs
were then cleaned of excess tissue and mounted on a glass slide in Vectashield®
mounting medium. Tissues were imaged at a final magnification of 100X utilizing a blue
filter to detect DAPI fluorescence and a green filter to detect EGFP fluorescence.
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2.3 Preparation of fly lines for use in tumor suppression studies
Mapping and balancing select fly lines
The transgene (lunasin or EGFP-lunasin) was mapped to either the X chromosome or
chromosome ii or iii. We mapped lines GEJ1-L5, and GEJ2-L3 and confirmed the
mapping done by GSI for lines GEJ1-L1- L3, and L8. Selected lines were balanced using
standard genetic cross schemes.
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3. RESULTS
3.1 Creation of transgenic Drosophila capable of expressing Lunasin and EGFP-Lun
Gene synthesis
We created transgenic flies that carried an EGFP tagged and an un-tagged version
of Lunasin. The tagged construct will allow us easily to visualize the expression and
localization of the protein. The untagged construct will allow us to determine whether
any effects demonstrated by EGFP-Lun are a result of the EGFP tag or Lunasin itself.
The genes coding for Lunasin and EGFP-Lunasin were synthesized by IDT. We then
cloned these genes into the Drosophila overexpression vector, pUAST (Figure 5.)
We obtained the sequence for Gm2S-1 from NCBI and used the primary structure
obtained from Lam et al. (2003) to identify the region coding for Lunasin. To generate
the EGFP-Lun fusion construct, we attached the sequence for EGFP to the 5’ end of
Lunasin; a study by Galvez et al. (1999) demonstrated that Lunasin tagged with GFP on
the N-terminus resulted in fluorescently labeled Lunasin with no observable differences
in bioactivity. To the untagged lunasin sequence, we added a start codon and stop codon
to ensure translation potential. Native Lunasin lacks translation start and stop sites as it is
part of a larger protein (Gm2S-1) that is post-translationally cleaved into smaller active
peptides (Figure1). Finally, to allow for directed cloning into pUAST, we placed the
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fragments and pUAST vector were gel extracted. Finally, lun and pUAST and EGFP-lun and pUAST were ligated.

First. pIDTSMART and pUAST vectors were digested with the restriction enzymes, EcoRI and XhoI. Gene

Figure 5. Schematic of the cloning process

restriction sites for EcoRI (G↓AATTC) and XhoI (C↓TCGAG) on the 5’ and 3’ end,
respectively, of our constructs (Figure 6.)
Gene constructs, lunasin and EGFP-lunasin, were synthesized by Integrated DNA
Technologies (IDT) and cloned into a plasmid vector, pIDTSMART (Figure 7).
pIDTSMART is a proprietary vector with a high copy number due to the pUC origin of
replication. Additionally, the plasmid contains an Ampicillin resistance marker, which
we used as a selection tool. The gene sequences were verified by IDT using M13 (-20)
Forward and M13 (-27) Reverse sequencing primers.

Cloning of lunasin and EGFP-lunasin into pUAST
pUAST is a Drosophila specific expression vector that, when injected into
Drosophila embryos along with a helper plasmid, integrates into the genome. pUAST
contains five GAL4 binding sequences, a multiple cloning site, and an Ampicillin
resistance gene (Figure 8).
We digested the plasmids (pUAST, pIDTSMART::EGFP-lun, and
pIDTSMART::lun) with the restriction enzymes, EcoRI and XhoI. Electrophoresis of the
resulting products revealed bands of approximately: 9 Kb (Figure 9a), 2 Kb and 850 bp
(Figure 9b), and 2 Kb and 150 bp (Figure 9c), which corresponded to the expected size
fragments from pUAST, pIDTSMART::EGFP-lun, and pIDTSMART::lun, respectively.
The bands corresponding to cut pUAST (~9 Kb), EGFP-lun (~850 bp), and lunasin
(~150 bp) were gel purified in preparation for the ligation of lunasin and EGFP-lun genes
into pUAST. DNA concentration and yield was determined via absorbance spectrums of
the purified DNA.
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Figure 6. Designed lunasin and EGFP-lun constructs utilized in this study
Lunasin and EGFP-Lunasin cDNA sequences with start (ATG) and stop (TAA)
codons flanked by EcoRI restriction site (G↓AATTC) on the N-terminus and XhoI
restriction site (C↓TCGAG) on the C-terminus.
lunasin and EGFP-lunasin constructs designed in silico to contain both start and
stop codons. Restriction sites for EcoRI and XhoI were added to allow for directed
cloning into pUAST. EGFP was fused to the 5’end of lunasin as per Galvez and
de Lumen (1999).
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Figure 7. Plasmid maps of synthesized gene constructs
lunasin and EGFP-lunasin (blue arrows) were synthesized and cloned into
pIDTSMART plasmid vectors containing an Ampicillin resistance gene, and pUC
origin of replication. Gene sequences were verified by IDT.
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Figure 8. Plasmid map of pUAST
pUAST contains an (a) Ampicillin resistance gene (red arrow), (b) five tandemly
arranged GAL4 binding domains, and a (c) multiple cloning site
Figure from(ADDGENE)Vector Database.
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Figure 9. Electrophoresis of plasmids digested with EcoRI and XhoI
Plasmids were digested with restriction enzymes, EcoRI and XhoI, and electrophoresed
on 1 % agarose gels stained with ethidium bromide in preparation for gel extractions of
(A) pUAST (8904 bp), (B) EGFP-Lun (864 bp), and (C) Lun (147 bp).
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The lunasin and EGFP-lun genes were ligated into pUAST and transformed into
competent DH5α E. coli. Only bacteria that carry plasmids containing the gene inserts
should have grown on Ampicillin selection plates. As digested pUAST has noncompatible sticky ends, the plasmid should not be capable of self ligation. Thus for a
bacterium to have a closed plasmid capable of conferring Ampicillin resistance, it must
be ligated to a fragment with compatible ends (i.e. digested lunasin or EGFP-lun).
Although unlikely, it is possible that two digested pUAST plasmids could fuse together,
resulting in one super-plasmid. As such, it was necessary to confirm the insertion of the
genes into pUAST.

Confirmation of successful cloning (pUAST::EGFP-lun and pUAST::lun)
The most direct method of confirming successful ligations of pUAST and
lunasin/EGFP-lun was to isolate plasmids from putative clones, digest the plasmid with
EcoRI and XhoI, and electrophorese the products. If we observed bands corresponding
to expected size fragments (for pUAST::lun clones, bands of ~9Kb and ~150 bp, for
pUAST::EGFP-lun clones, bands of ~9 Kb and ~850 bp) we could conclude that the
clone was likely to be correct.
Figure 11illustrates one such trial resulting in two distinct DNA bands at
approximately 8.9 Kb and 850 bp, corresponding to pUAST and EGFP-lun, respectively.
Thus, this sample, E9, was chosen for sequencing to ensure that no mutations had
zoccurred.
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Figure 10. Gel analysis of pUAST::EGFP-lun clone
Digestion of putative pUAST::EGFP-lun clone (lane ‘E9’) with EcoRI and XhoI
produced fragments of 2 sizes: one of approximately 9 kb corresponding with pUAST,
and another of approximately 850 bp corresponding with EGFP-lun.
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This approach was not useful for confirming pUAST::lun clones. Attempts to
visualize digested lunasin bands from putative clones repeatedly failed, and it was
ultimately deduced that lunasin, being only 147 bp, was not present in high enough
concentrations to be visualized via gel electrophoresis.
To circumvent this obstacle, we performed whole colony PCR on putative
pUAST::lun clones, utilizing two oligonucleotide primers which flank the multiple
cloning site: pUAST.FOR and GEJ.pUAST.REV (Table 5). When electrophoresed,
empty pUAST generates a fragment of 377 bp while a successful clone generates a band
of 490 bp. Samples were run alongside a 1 Kb+ ladder and a positive control for empty
pUAST. Lanes 2-5, 7 and 8 contain bands of approximately 500 bp indicating
recombinant pUAST plasmids (Figure 11).
Recombinant plasmids, pUAST::EGFP-lun and pUAST::lun, were isolated from
liquid cultures to prepare samples for sequencing and microinjection into Drosophila
embryos. Plasmid isolation (Maxiprep) of pUAST::EGFP-lun (sample E9) yielded 97
μgs of plasmid DNA with an OD260/OD280 of 1.90 (Supplementary figure 2a). Plasmid
isolation of pUAST::lun (sample 1b) yielded 941 μgs of plasmid DNA with an
OD260/OD280 of 1.93 (Supplementary figure 2b).
Before sending our recombinant pUAST constructs for microinjection, we
sequenced each clone to ensure the integrity of lunasin or EGFP-lun. A change in
nucleotide compositions in these genes could change the primary structure of the
translated peptide,
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Figure 11. Gel analysis of potential pUAST::lun clones
Whole colony PCR conducted on transformed colonies results in two possible band
sizes. Empty vector generates a 377 bp fragment; the presence of lunasin generates
a 490 bp fragment. Lane 1 contains empty pUAST as a positive control for empty
vector. Lanes 2-9 contain potential clones. Samples in lanes 2-5, 7, and 8 show
bands at 490 bp. Samples in lanes 6 and 9 show a band at approx 377 bp.
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which may affect the 2° and 3° protein structures and consequently alter the behaviour of
the protein in vivo.
The resulting sequences for pUAST::EGFP-lun and pUAST::lun (Supplementary
figure 3 and Supplementary figure 4) matched the gene sequences synthesized by IDT
(Figure 12 and Figure 13). Once we confirmed that the pUAST constructs contained the
correct gene sequence with no alterations, we sent between 50 and 100 μgs of
recombinant plasmid (Figure 14) to GSI to be microinjected into Drosophila embryos.

Microinjection of recombinant pUAST constructs
Microinjection has a low success rate as Drosophila embryos are delicate and
often die when the waxy, vitelline membrane is punctured. Even microinjecting several
hundred embryos may yield only a handful of viable individuals. We received eight
EGFP-Lun transgenic lines (GEJ1-L1 to L8) and five untagged Lunasin transgenic lines
(GEJ2-L1 to L5) from GSI.

3.2 Assessing the effects of Lunasin on Normal development
Confirmation of EGFP-Lun overexpression
To confirm expression in EGFP-lun transgenics, we crossed transgenics to
Tubulin-GAL4 and visualized the larvae via fluorescence microscopy (Figure 15).
Progeny of GEJ1-L1 through GEJ1-L8 crossed with Tubulin-GAL4 all fluoresced when
placed under blue light indicating that each line was capable of expressing EGFP-Lun
when under control of a GAL4 driver.

41

Figure 12. Sequence alignment of EGFP-lun
Sequence alignment was performed using bioinformatics software (ClustalW2).
Sequence 1 (EGFP__Lun) is the sequence for EGFP-lun as synthesized by IDT.
Sequence 2 (sampleUAAS-2) is the experimental data from the sequencing of
potential clone, E9. Stars (*) below the sequences identify nucleotide homology.
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pUAST::Lun
pUASTLunSEQ5

TAAAGTGAATCAATTAAAAGTAACCAGCAACCAAGTAAATCAACTGCAACTACTGAAATC 360
-----------------------------------------------------CGTCATC 7
*:.***

pUAST::Lun
420
pUASTLunSEQ5

TGCCAAGAAGTAATTATTGAATACAAGAAGAGAACTCTGAATAGGGAATTGG|GAATTCAT

pUAST::Lun
pUASTLunSEQ5

GTCCAAATGGCAGCACCAGCAAGATAGCTGCCGCAAGCAGCTCCAGGGGGTGAACCTCAC 480
GTCCAAATGGCAGCACCAGCAAGATAGCTGCCGCAAGCAGCTCCAGGGGGTGAACCTCAC 123
************************************************************

pUAST::Lun
pUASTLunSEQ5

GCCCTGCGAGAAGCACATCATGGAGAAGATCCAAGGCCGCGGCGATGACGATGATGATGA 540
GCCCTGCGAGAAGCACATCATGGAGAAGATCCAAGGCCGCGGCGATGACGATGATGATGA 183
************************************************************

pUAST::Lun
pUASTLunSEQ5

TGACGACGACTAACTCGAG|GGTACCTCTAGAGGATCTTTGTGAAGGAACCTTACTTCTGT600
TGACGACGACTAACTCGAG|GGTACCTCTAGAGGATCTTTGTGAAGGAACCTTACTTCTGT243
*******************|*****************************************

pUAST::Lun
pUASTLunSEQ5

GGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAA 660
GGTGTG-----------------ACCAACGGTTAATTGATTCACTTTG------------ 274
******
***:**.*: *:**.*: *:**::*

TGCCAG--AG-TATTATTG-ATACAAGAAGAGAACTCTGAATAGGGAATTGG|GAATTCAT 63
*****. ** :******* ********************************|********

Figure 13. Sequence alignment of pUAST::lun
Sequence alignment was performed using ClustalW2 bioinformatics software.
“pUAST::Lun” is the constructed sequence of pUAST::lun (assembled from the sequence
of pUAST and the sequence of our synthesized lunasin) and “pUASTLun SEQ5” is the
experimental sequence obtained from pUAST::lun clone, 1b. Aqua shading denotes
lunasin, whereas gray represents pUAST sequence flanking the lunasin insert.
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Figure 14. Plasmid maps of pUAST clones
Recombinant pUAST constructs contain 5X GAL4 binding sites, an Ampicillin
resistance gene, and a multiple cloning site where EGFP-lunasin (A) and lunasin (B)
was inserted.
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Figure 15. GAL4 mediated overexpression cross scheme
Virgins of the GAL4 line are crossed with transgenic/UAS males. In this instance,
Tubulin-GAL4/Tm3Sb virgins are crossed with EGFP-Lun transgenics. Offspring
will be either UAS EGFP-Lun/Tubulin-GAL4 or UAS EGFP-Lun/Tm3Sb. UAS
EGFP-Lun/Tubulin-GAL4 individuals will fluoresce under blue light (490 nm).
(Adapted from (DUFFY 2002).
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Forcing ectopic expression of EGFP-Lun
Once we established that EGFP-Lunasin was being expressed in our transgenic
lines, we sought to assess whether this expression affected normal development of
Drosophila by examining animals for gross phenotypic abnormalities. To drive
expression of EGFP-Lun in a tissue specific manner, we employed the GAL4/UAS
system. Progeny resulting from crosses between EGFP-Lun transgenic lines (GEJ1-L1 to
GEJ1-L8) and GAL4 driver lines showed no phenotypic abnormalities (Table 6). Not
every transgenic line was crossed with all ten GAL4 drivers. However, it is most
important to note that for each transgenic line, when EGFP-Lun was expressed
ubiquitously (i.e. under control of Tubulin-GAL4 driver), there were no observed
phenotypic abnormalities. This suggests that if EGFP-Lun expression were to be
restricted to a portion of the body, there would likewise be no resulting abnormalities.

Subcellular localization of EGFP-Lun
Native Lunasin is known to localize to the nucleus, and thus it was necessary to
ensure that EGFP-Lun acted in the same way. If EGFP-Lun does not localize to the
nucleus, any conclusions concerning the effects of Lunasin on normal development
would be irrelevant. To determine the subcellular localization of EGFP-Lun, we imaged
animals expressing EGFP-Lun in the salivary glands. Cells in the salivary glands
undergo multiple rounds of DNA replication without completing cytokinesis, resulting in
polytene chromosomes and enlarged nuclei to house the chromosomes. These enlarged
nuclei allow for simple imaging of the cells.
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GAL4 Driver Lines
Cg-GAL4,UAS-GFP/CyO
w;Ey-GAL4/CyO
GMR-GAL4
w;LSP2-GAL4
Pnr-GAL4/Tm6Tb
Ptc-GAL4,UAS-GFP
Sd-GAL4 (x)
yw;;Tub-GAL4/Tm3Sb
w;;Ubx-GAL4/Tb
Vg-GAL4 (M+Q)

GEJ1
-L1
X
X
X
x
X
X
X
-

GEJ1
-L2
X
X
X
X
X
X
X
X
X
X

GEJ1
-L3
X
X
X
X
X
X
X
X

GEJ1
-L4
X
X
X
X
-

GEJ1
-L5
X
X
X
-

GEJ1
-L6
X
X
X
X
X
-

GEJ1- GEJ1L7
L8
X
X
X
X
-

X = progeny of cross were viable and exhibited no phenotypic abnormalities
- = cross not conducted

Table 6. Summary of UAS-EGFP-lun crosses to various GAL4 lines
When crossed to Tub-GAL4, which drives ubiquitous expression of UAS constructs
(EGFP-Lun, in this instance), progeny exhibited no phenotypic abnormalities.
GEJ1-L2 was crossed to each GAL4 driver and similarly exhibited no phenotypic
abnormalities.
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Ey-GAL4 and Sd-GAL4 are known to drive expression of EGFP-Lun in the
salivary glands. Progeny resulting from crosses between our transgenic GEJ1-L2 and
these GAL4 lines express EGFP-Lun in the salivary glands. Glands were mounted in
Vectashield with DAPI® as this medium greatly slows degradation of fluorescent signals
while staining the nucleus with DAPI. In this way, we were able to compare the location
of EGFP-localization to those of nuclear boundaries. Our results revealed direct
alignment between nuclear boundaries and EGFP-Lunasin localization regions (Figure
16) indicating that, when expressed in Drosophila, EGFP-Lun localizes to the nucleus.

3.3 Development of tools to be utilized in tumor suppression studies.
Mapping transgenes to specific chromosomes
Mapping transgenes to specific chromosomes allows investigators to track the
presence of these genes when conducting crosses, thus it was essential that we map the
location of our transgenes. To do this, we first determined whether the transgene is
located on an autosome (ii or iii) or X chromosome by crossing virgin double balanced
flies (w; Sco/CyO; Sb/TM6Tb) with male transgenic flies. If the transgene is on an
autosome, both male and female progeny will be a mix of red eyed (w+) and white eyed
(Figure 17). If on the X chromosome, all male progeny will have white eyes (w), and
females will have a mix of red and white eyes, as male progeny receive the Y
chromosome from the transgenic male, and therefore would not receive a copy of the
transgene (marked by presence of w+).
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demonstrates overlap of expression area.

with (A) a blue filter detect DAPI fluorescence and (B) a green filter show EGFP-Lun localization. A composite image (C)

mounting medium with DAPI, a nuclear stain. Fluorescence microscope images of salivary glands expressing EGFP-Lun

EGFP-Lun expression was driven in salivary glands. Glands were dissected, preserved, and mounted in Vectashield ®

Figure 16. Localization of EGFP-Lun to Nucleus

Figure 17. Schematic for mapping transgene to either X chromosome or
autosomes
To determine if transgene is inserted on X chromosome or an autosome, male
transgenics are crossed with double balanced virgins (F0). If the transgene (pw+) is
inserted on the X chromosome, male progeny (F1) will all be white eyed (w). If on
an autosome, male progeny will be a mix of white eyed (w) and red eyed (w+).

50

If the transgene is on an autosome, we then set out to determine onto which
chromosome, ii or iii, the trangene inserted (Figure 18). Our transgenics were created
utilizing Flipase mediated recombination, and as crossing over and recombination do not
occur on chromosome iv (or the Y chromosome) of Drosophila (SANDLER and SZAUTER
1978), transgenes do not insert on chromosome iv. We determined whether the transgene
was inserted on chromosome ii or iii by crossing selected progeny (w+, CyO, Tb) from
the cross described above (☿double balanced x ♂ transgenics) with double balanced
virgins (Figure 18). If the resulting w+ progeny are Sco/CyO, the transgene must be on
chromosome iii. Conversely, if the w+ progeny are Sb/Tb, the transgene is necessarily on
chromosome ii.
GEJ1 transgenic lines L1-L3, and L8 were mapped by GSI (Table 7) and later
confirmed by our lab. The transgene for L1 inserted on the X chromosome, L2 mapped
to chromosome iii, and L3 and L8 mapped to the ii chromosome. We mapped GEJ1-L5
and GEJ2-L3 to the X chromosome.

Balancing transgenic lines
A balanced line provides a stable, self perpetuating stock that ensures a consistent
genotype. Because we set out to create tools for use in tumor suppression studies, we
chose to balance a line that would be the most useful in this study. We chose to balance
GEJ1-L2 because the EGFP-lun transgene was mapped to chromosome iii and the mutant
genes for the selected tumor modeling system, RasV12/lgl, are located on the chromosome
ii. To ensure that both introduced chromosomes (transgene and invasive tumor gene) are
maintained together in the stock, each need to be balanced over a balancer chromosome.
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Thus, a transgenic line in which EGFP-lun is on chromosome iii is ideal for tumor
studies utilizing RasV12/lgl flies.
To balance GEJ1-L2, we first crossed our transgenic line to a double balanced
line (Figure 19). Male w; +/CyO; pw+/Tb progeny were then selected and recrossed to
virgin double balanced flies. Male and virgin females of the target genotype (w;
Sco/CyO; EGFP-Lun/TM6Tb) were then crossed to produce a stable, balanced line.
GEJ1-L2 was successfully balanced and has the genotype: w; Sco/CyO; w+,EGFPLun/TM6Tb. This line is now available for use in tumor suppression studies.
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Figure 18. Schematic for mapping to chromosome ii or iii
(F0) Cross w+ males with double balanced virgins (w; Sco/Cyo; Sb/TM6Tb). (F1) Select
w+; CyO; Tb male progeny and cross once more with double balanced virgins.
Determine whether pw+ is on chromosome ii or iii. If w+ animals (F2) are Sb/Tb, then the
transgene inserted on chromosome ii; if w+ animals are Sco/CyO, the transgene inserted
on chromosome iii.
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Homozygous
Line Name Chromosome

Lethal (Y/N)

GEJ1-L1

X

GEJ1-L2

iii

N

GEJ1-L3

ii

N

GEJ1-L4*
GEJ1-L5

X

GEJ1-L6*
GEJ1-L7*
GEJ1-L8

ii

Line Name X chromo.

Y

Autosome

GEJ2-L1*
GEJ2-L2

no

yes

GEJ2-L3

yes

no

no

yes

GEJ2-L4*
GEJ2-L5

Table 7. Transgenes mapped to specific chromosomes
Lines in which no mapping data were collected are denoted with an asterisk (*).
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Figure 19. Schematic for balancing transgenic line, GEJ1-L2
For balancing a line that has the transgene on the third chromosome such as GEJ1L2, select red eyed (w+) transgenics and cross to the double balanced line (w;
Sco/CyO; Sb/TM6Tb). Select w; +/CyO; pw+/Tb progeny and mate once more with
the double balanced line. From the progeny, select w+, Sco/Cyo, and Tb virgins
and males and cross to each other to maintain a balanced line.
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4. DISCUSSION and FUTURE DIRECTIONS
Lunasin has been shown to exhibit anti-metastatic activities in newly transformed
cell lines, while having no effect on the health or mitotic abilities of non-tumorigenic cell
lines (DE LUMEN 2005; DIA and GONZALEZ DE MEJIA 2011; LAM et al. 2003; PABONA et
al. 2012). All of these experiments were conducted in vitro and therefore it was not
known how Lunasin acts when expressed in vivo. To advance Lunasin as a
chemotherapeutic agent, model organisms capable of overexpressing Lunasin must be
developed, and in vivo studies must be conducted to predict how Lunasin might act in
humans. We predicted that Lunasin would not impart any phenotypic effects when
expressed in non-tumorigenic Drosophila. The lack of phenotypic abnormalities in
EGFP-Lunasin expressing individuals would contribute to the body of evidence
supporting the therapeutic potential of Lunasin. Additionally, the tools created in this
study can be used in future studies (e.g. tumor suppression, and Alzheimer’s and
Parkinson’s diseases).

Transgenic Drosophila are capable of expressing Lunasin and EGFP-Lun.
Animal models are essential in studying the in vivo effects of drugs, and
Drosophila provides a convenient and powerful tool to model many disease states,
including tumorigenesis and metastasis (PAGLIARINI and XU 2003; RUDRAPATNA et al.
2012). We set out to create transgenic Drosophila that are capable of overexpressing
Lunasin and a tagged Lunasin construct for use in developmental and tumor suppression
studies.
The successful construction of pUAST::EGFP-lun and pUAST::lun plasmids for
microinjection into Drosophila embryos was confirmed through sequencing efforts
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(Figure 12 and Figure 13). Our results show that our EGFP-lun transgenic lines were
capable of producing EGFP-Lunasin.

EGFP-Lun localizes to the nucleus.
We chose to create a fluorescently tagged Lunasin construct to allow for
visualization of the Lunasin peptide in subsequent studies. This fusion protein (EGFPLun), when excited with blue light, allows us to easily confirm Lunasin expression as
well as monitor the expression location and, to a limited degree, gauge expression levels.
However, in order to make relevant conclusions regarding the effects of EGFP tagged
Lunasin in vivo, it was first necessary to establish that this fluorescently tagged construct
acts in the same way as untagged Lunasin. Native Lunasin localizes to the nucleus, and
although it remains unclear how this occurs, it is suggested that this behaviour is required
for the observed anti-mitotic bioactivity attributed to Lunasin. (DE LUMEN 2005; GALVEZ
et al. 2001; GALVEZ and DE LUMEN 1999). Our findings demonstrate that EGFP-Lun
indeed localizes to the nucleus, suggesting that our EGFP-Lun construct acts in a way
similar to untagged Lunasin and thus may potentially be used in place of untagged
Lunasin in future studies. However, as Lunasin is less than one fourth the size of EGFP,
it is possible that the added mass may cause steric hindrance and alter the bioactivity of
the fusion protein. Thus, it is essential that additional assays (i.e. microarrays) be
conducted to ensure that the effects of tagged Lunasin mirror that of untagged Lunasin at
a molecular level.

In non-tumorigenic flies, expression of EGFP-Lunasin results in no phenotypic
abnormalities.
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Many chemotherapeutics have the undesirable side effect of killing healthy cells
and cancerous cells. Previous in vitro studies have demonstrated that Lunasin selectively
inhibits mitosis and induces apoptosis in newly transformed cells while having no
deleterious effects on the health or mitotic ability of non-tumorigenic cell lines (DE
LUMEN 2005; DIA and GONZALEZ DE MEJIA 2011; GALVEZ et al. 2001; LAM et al. 2003;
PABONA et al. 2012). Although this makes Lunasin a desirable candidate for
development as a therapeutic, these studies have solely been conducted in cell cultures.
We sought to determine if the overexpression of Lunasin in vivo affects normal
development. Our findings demonstrate that, when expressed ubiquitously, EGFP-Lun
results in viable individuals with no phenotypic abnormalities. Although no effects were
noticeable at the organism level, it is important to also identify changes at the molecular
level.

Tools developed for use in tumor suppression studies.
We have created tools that will allow us to assess the therapeutic potential of
Lunasin by determining whether Lunasin has anti-tumorigenic and/or anti-metastatic
effects in vivo by visualizing size and metastasis of tumors in Drosophila. One such tool
is the balanced transgenic line. Balancer chromosomes allow for the maintenance of
heterozygous stocks while allowing recessive lethal mutations to be preserved in a
population. Transgenes inserted into the Drosophila genome can often be selected
against and after several generations may be lost. Therefore, it is essential that these
transgenes be balanced. Transgenic line GEJ1-L2, with EGFP-Lun mapped to the
chromosome iii, is balanced and primed to be used in tumor suppression studies utilizing
the Drosophila tumor invasion model.
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4.1 Future Directions
The EGFP-Lun transgenic flies created in this study have the potential for great
utility in understanding the effects of Lunasin in many disease backgrounds. However, in
order to conclusively demonstrate this utility, we must show that our EGFP-Lun lines act
in an identical manner to un-tagged Lunasin. This requires that we first show that our
untagged-Lunasin transgenic lines express Lunasin. This can be accomplished the
RTPCR confirmation of lunasin mRNA. At the time of this writing, RTPCR experiments
are underway.
In addition to assessing overall tumor growth, it would be beneficial to study
differences in tumor composition. Lunasin has been found to increase CDK-inhibitors
(p21 and p27) in colon cancer cells and mouse embryo fibroblasts in vitro (DIA and
GONZALEZ DE MEJIA 2011; LAM et al. 2003). Additionally, Lunasin modifies expression
levels of ECM genes (Table 2) in a human colon cancer cell line (KM12L4). As these
have been demonstrated in vitro, it is essential that the effects of Lunasin, on a molecular
scale, be investigated in vivo. By running a microarray on tumors in animals expressing
Lunasin and on tumors in those not expressing Lunasin, we can investigate how Lunasin
affects protein levels (i.e. p21, p27, and ECM genes) in tumor environments.
In order to make generalizations regarding the efficacy of Lunasin as an anticancer therapeutic in vivo, it is imperative to study the effects of Lunasin in multiple in
vivo tumor models. In addition to the RasV12/lgl tumor model, scrib-/- mutants are often
employed in tumor studies as RasV12/scrib-/- animals develop tumors with metastatic
capabilities (PAGLIARINI and XU 2003). By employing this tumor model, we can observe
gross growth rates of tumors in the presence of lunasin and without, and also conduct
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protein micro-arrays to compare to changes in protein levels between the tumor
backgrounds.
Lunasin has also been found to inhibit inflammation by reducing expression
levels of proinflammatory cytokines (LIU and PAN 2010). Inflammation has been
implicated in several human ailments including Alzheimer’s disease (AD) and
Parkinson’s disease (PD). There are Drosophila models for AD and PD which could be
utilized in conjunction with the transgenic flies developed in this study to assess the
effects of Lunasin on the disease pathology. If Lunasin reduces pathogenicity of these
diseases (AD, PD, and cancer) in Drosophila then it would be valuable to assess the
effects of Lunasin on disease progression in a mammalian model more closely related to
humans than flies.
Cancers have been a concern for human health, but neoplasias are becoming a
conservation concern as well. Tasmaniam devil facial tumors, genital carcinomas in
California sea lions and several dolphin species, and fibropapillomas in Green Sea
Turtles are threatening the future of these species (MCALOOSE and NEWTON 2009).
Lunasin also may hold some promise in combating these novel wildlife neoplasias as
Lunasin works in many ways to limit tumorigenesis.
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APPENDIX
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Supplementary figure 1. 1 Kb+ ladder
This DNA ladder was used throughout the cloning process to estimate fragment
size of electrophoresed DNA samples. The doublet at 2 Kb and 1650 bp
provide a distinct reference for enumerating the ladder bands.
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Supplementary figure 2. Absorption spectrum of (A) pUAST::EGFP-lun clone
(sample E9) and (B) pUAST::lun (sample 1b) .
Spectroscopy readings of isolated pUAST::EGFP-lun (A) revealed an OD260/OD280 of
1.90 and a yield of 97 μg; while isolated pUAST::lun has an OD260/OD280 of 1.93 and
yielded 941 μg. Absorption spectrum of (A) pUAST::EGFP-lun clone (sample E9) and
(B) pUAST::lun (sample 1b) .
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Supplementary figure 3. Sequence data for pUAST::EGFP-lun clone, E9
EGFP-Lun begins at bp 66 and extends to bp 917. Bp 1-65 and 918-1186 represent
pUAST sequence. Color and height of the bars correspond to nucleotide call confidence:
blue indicates a call of high confidence, yellow of intermediate confidence, and red
indicates a poor read with low confidence. Tall bars represent higher confidence than
shorter bars.
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Supplementary figure 4. Sequence data for pUAST::lun clone, 1b
lunasin begins at bp 62 (ATG) and extends to bp 196. Bp 1-61 and 197-579 represent
pUAST sequence. Color and height of the bars correspond to nucleotide call confidence:
blue indicates a call of high confidence, yellow of intermediate confidence, and red indicates
a poor read with very low confidence. Tall bars represent higher confidence than short bars.
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Protocol 1. Restriction Digest (double)
Reagent

Volume/Amount

EcoRI

1 µL

XhoI

1 µL

10X Buffer H

2 µL

Substrate DNA

≤1 µg

Sterile water

to 20 µL

1. Combine reagents in PCR tube according to table above. Add enzymes last.
2. Incubate in thermal cycler at 37 °C for 1 hr.
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Protocol 2. Gel Extraction (QIAGEN; cat. no. 20021)
1. Excise DNA band from the agarose gel using a razor blade.
2. Weigh the gel slice. Add Buffer QX1 (and water) according to table below:
DNA fragment size :
100 bp – 4 kb
>4 kb

DNA fragment:

Amount reagent:

Lunasin and EGFP-Lun

3 volumes Buffer QX1

pUAST

3 volumes Buffer QX1
plus 2 volumes of H2O

Ex. If Lunasin fragment slice weighs 150 mg, add 450 µL Buffer QX1
3. Resuspend QIAEX II by vortexing for 30 s. Add QIAEX II to the sample
according to the table below and mix:
Amount DNA:

Amount QIAEX II:

≤ 2 ug DNA

Add 10 µL of QIAEX II

2-10 ug DNA

Add 30 µL of QIAEX II

4. Incubate at 50 °C for 12 minutes. Mix by vortexing every 2 minutes.
5. Centrifuge the sample at 10,000 X g for 30 s and carefully remove supernatant
with a pipet.
6. Wash the pellet with 500 µL Buffer QX1. Vortex the pellet, centrifuge at 10,000
x g for 30 s, and remove supernatant with pipet.
7. Wash the pellet twice with 500 µL of Buffer PE. Vortex the pellet, centrifuge for
30 s, and remove supernatant with a pipet. Repeat for second wash.
8. Air-dry the pellet for 10-15 min. To speed up drying, apply a vacuum until the
pellet becomes white.
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9. To elute the DNA, add 20 µL water and resuspend the pellet by vortexing.
Incubate according to the table below.
Fragment size:

DNA fragment:
Lunasin

DNA fragments ≤4 kb

and EGFP-Lun

Incubation directions:
Incubate at room temp.
(25 °C) for 5 min
Incubate at 50 °C for

pUAST

DNA fragments 4-10 kb

5 min

10. Centrifuge for 30 s. Pipet the supernatant into a clean microcentrifuge tube.
11. Analyze purity and concentration via NanoDrop spectrometer.
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Protocol 3. Ligation (New England BioLabs; cat. no. M0202S.)
Reagent:

Volume/Amount:

Plasmid DNA

**

Insert DNA

**

10X ligase buffer

2 µL

T4 DNA ligase

1 µL

Sterile water

to 20 µL

1. Set up ligation reactions as described in table above.
2. Incubate at 10 °C for 16 hrs.

** Determine amount of DNA to be ligated (100-300 ng), choose vector: insert ratio
(1:3, 1:9, 1:20 etc.), and calculate volume of plasmid and vector DNA to ligate.
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Protocol 4. Transformation
1. Chill ligation reaction and DH5α competent cells on ice.
2. Combine 100 µL DH5α cells with 10 µL ligation reaction.
3. Combine 100 µL DH5α cells with 10 µL water (negative control)
4. Heat shock at 42 °C for 90 s.
5. Place mixtures on ice for 2 min.
6. Add 500 µL Luria Broth
7. Incubate mixture at 37 °C for 45 min with shaking (225rpm)
8. Plate 300 µL of mixture on LB-Amp (50 µg/mL) plates.
9. Incubate at 37 °C for 16-20 hours.

Note: Resulting colonies contain the Ampr gene.
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Protocol 5. Plasmid isolation – Mini (QIAGEN; cat. no. 27104)
1. Pick a single colony from a freshly streaked Ampicillin selection plate and
inoculate a starter culture of 5 mL LB-Amp (50 µg/mL). Incubate for 8-12 hours
at 37 °C with vigorous shaking.
2. Centrifuge cells at 3,000 x g for 5 min at 4 °C
3. Resuspend pelleted cells in 250 µL Buffer P1 and transfer to a microcentrifuge
tube.
4. Add 250 µL Buffer P2 and invert tube 6 times.
5. Add 350 µL Buffer N3 and invert tube 6 times.
6. Centrifuge for 10 min at 13,000 rpm in a table-top centrifuge.
7. Apply supernatant from step 6 to QIAprep spin column.
8. Centrifuge for 60 s. Discard flowthrough.
9. Wash the QIAprep spin column by adding 0.5 mL Buffer PB and centrifuge at
13,000 rpm for 60 s.
10. Discard flowthrough and centrifuge an additional 60 s.
11. Elute DNA into clean microcentrifuge tube by adding 50 µL Buffer EB to center
of the QIAprep spin column, let stand for 1 min, and centrifuge for 1 min.

71

Protocol 6. Whole colony PCR
Reagent:

Volume/Amount:

SuperMix

22.5µL

Forward Primer

200 nM

Reverse Primer

200 nM

Sterile water

to 25 µL
1

Transformed colony

1.

Set up reactions according to the table above.

2. Load into Thermal Cycler and set the PCR parameters as follows:
Initial denaturation:

95 °C for 3 min

30 cycles of:
Denaturation:

95 °C for 40 s

Annealing:

57 °C for 30 s

Extension:

72 °C for 30 s

Final extension:

72 °C for 4 min

Hold:

4 °C for ∞
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Protocol 7. Plasmid Isolation – Maxi (QIAGEN; cat. no. 12963)
1. Pick a single colony from a freshly streaked Ampicillin selection plate and
inoculate a starter culture of 2-5 mL LB-Amp (50 ug/mL). Incubate for 8-12
hours at 37 °C with vigorous shaking (250-300 rpm).
2. Inoculate 300-500 mL LB-Amp (50 µg/mL) with 150 µL of starter culture.
Incubate for 12-16 hrs at 37 °C with vigorous shaking (250 rpm).
3. Centrifuge cells at 6,000 x g for 15 min at 4 °C
4. Discard supernatant and resuspend pellet in 10 mL buffer P1.
5. Add 10 mL Buffer P2, mix by inverting the tube 6 times and incubate at room
temperature (25 °C) for 5 min.
6. Add 10 mL chilled Buffer P3, invert 6 times, and incubate on ice for 20 min.
7. Centrifuge at 20,000 x g for 30 min at 4 °C.
8. Immediately transfer supernatant and recentrifuge at 20,000 x g for 15 min at
4 °C. Immediately transfer supernatant to clean vial.
9. Equilibrate a QIAGEN-tip 500 by applying 10 mL Buffer QBT, and allow the
column to empty by gravity flow.
10. Apply the supernatant from step 8 to the QIAGEN-tip and assist the flow by
applying a vacuum to the tip.
11. Wash the QIAGEN-tip with 2 x 30 mL Buffer QC and assist the flow by applying
a vacuum to the tip.
12. Elute the DNA with 15 mL Buffer QF. Collect elute.
13. Precipitate DNA by adding 10.5 mL room temp Isopropanol to the eluted DNA.
Mix and centrifuge at 15,000 x g for 30 min at 4 °C. Decant supernatant.
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14. Wash DNA pellet with 5 mL room temp 70 % ethanol. Centrifuge at 15,000 x g
for 10 min. Decant supernatant, being cognizant to not disturb the pellet.
15. Air-dry the pellet for 10 min and redissolve the DNA in 800 µL water.
16. Analyze DNA via NanoDrop spectrometer.
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*Concluded that DTP activity differs not only between neoplastic and normal
individuals, but also among neoplastic individuals
Mercyhurst University
Erie, PA
Research Assistant; Advisor: Steve Mauro, Ph.D.
2009-2011
Elucidating factors leading to the induction of lytic phase in bacteriophage λ in E. coli
*Worked to elucidate factors influencing the shift from lysogenic to lytic cycle
by employing PCR, spectroscopy, bioinformatics, and plating techniques
Mercyhurst University
Erie, PA
Research Assistant; Advisor: John Campbell, Ph.D.
Winter 2009
Factors influencing tumor growth in the Brown Bullhead of Presque Isle, Erie, PA
*Tested how different variables (light frequencies and intensities, water depth, and
water temperature) affected the behavior of brown bullheads, Ameiurus nebulosus.
TEACHING EXPERIENCE
Western Kentucky University
2011-2013
Graduate Teaching Assistant: Cellular and Molecular Biology Lab (Bio 322).
*Taught two sections of the Cellular and Molecular Biology lab each semester;
*Prepared materials for each lab period (i.e. buffers, media plates, media, stock
solutions, etc.);
*Updated course materials to match the objectives of the class
Mercyhurst University
Academic Tutor: Organismal Biology, Cell Biology, Ecology, Chemistry
*Clarified concepts for students in order to increase understanding;
*Developed study plans
83

2009-2010

PRACTICAL EXPERIENCE
Lost River Cave
Bowling Green, KY
Tour Guide and Gift Shop Cashier
2012
*Develop and lead interpretive tours incorporating the history, geology, and biology of
the cave and river system.
Mercyhurst University Biology Department
Erie, PA
Animal Caretaker
2010-2011
* Cleaned and maintained 1-180 gal marine tank and 1-180 gal freshwater, lake tank;
* Purchase supplies for maintenance of tanks and animals
Mercyhurst University Residence Life
Erie, PA
Resident Assistant
2009-2011
* Created a friendly, respectful and considerate environment among the residents;
* Met with residents expressing concern (roommate conflicts, personal issues, etc.);
* Completed duty rounds to promote the safety and security of the campus
community
Mercyhurst University Forensics Department
Erie, PA
Student Assistant
2008-2010
* Processed human and animal remains;
* Assisted with Bomb Blast Recovery short course;
* Ensured sanitary conditions in laboratory for health and safety;
* Assisted with NIJ awarded grants: “Recovery and Interpretation of Burned Human
Remains”; “Enhancing Scene Processing Protocols to Improve Victim Identification
and Field Detection of Human Remains at Mass Fatality Scenes."
* Resident assistant for summer Forensic short courses
PRESENTATIONS
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tumor progression in Drosophila melanogaster.” Graduate Student Research
Symposium. Western Kentucky University. Bowling Green, KY.
GE Jones. 2010. “Multidrug resistance activity in Mytilus trossulus: A comparison of
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